Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
February 13, 2025 18:37 ET
|
Mesoblast Limited
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently...
Ryoncil® Commercial Launch Update and Product Pipeline
January 30, 2025 19:11 ET
|
Mesoblast Limited
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
January 30, 2025 18:20 ET
|
Mesoblast Limited
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024 19:08 ET
|
Mesoblast Limited
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers,...
Mesoblast to be Added to Nasdaq Biotechnology Index
December 18, 2024 07:30 ET
|
Mesoblast Limited
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition...
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
December 04, 2024 18:32 ET
|
Mesoblast Limited
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States Food...
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
December 02, 2024 18:20 ET
|
Mesoblast Limited
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced a key publication in...
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
October 30, 2024 19:11 ET
|
Mesoblast Limited
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
September 29, 2024 20:55 ET
|
Mesoblast Limited
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a...
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
August 28, 2024 19:27 ET
|
Mesoblast Limited
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update...